DrugPatentWatch Database Preview
Drugs in Development Information for Fotemustine
Drug Development Status for Fotemustine: Patents, clinical trial progress, indications
Fotemustine is an investigational drug.
There have been 16 clinical trials for Fotemustine.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.
There is one US patent protecting this investigational drug and twenty-five international patents.
Summary for Fotemustine
| US Patents | 1,979 |
| International Patents | 25,973 |
| US Patent Applications | 6,071 |
| WIPO Patent Applications | 1,881 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2012-06-01) |
| Vendors | 63 |
Recent Clinical Trials for Fotemustine
| Title | Sponsor | Phase |
|---|---|---|
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | Mingzhi Zhang | Phase 4 |
| A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT | Genenta Science | Phase 1/Phase 2 |
| MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | Azienda Sanitaria di Firenze | Phase 2/Phase 3 |
Clinical Trial Summary for Fotemustine
Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine
US Patents for Fotemustine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fotemustine | Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | Start Trial |
| Fotemustine | Start Trial | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Fotemustine | Start Trial | Anti-FGFR3 antibodies and methods using same | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Fotemustine | Start Trial | Bispecific antigen-binding constructs targeting HER2 | Zymeworks Inc. (Vancouver, CA) | Start Trial |
| Fotemustine | Start Trial | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | Start Trial |
| Fotemustine | Start Trial | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fotemustine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fotemustine | World Intellectual Property Organization (WIPO) | 2015148714 | 2034-03-25 | Start Trial |
| Fotemustine | Australia | 2015231053 | 2034-03-21 | Start Trial |
| Fotemustine | Brazil | 112016021620 | 2034-03-21 | Start Trial |
| Fotemustine | Canada | 2943339 | 2034-03-21 | Start Trial |
| Fotemustine | China | 106231900 | 2034-03-21 | Start Trial |
| Fotemustine | Eurasian Patent Organization | 201691896 | 2034-03-21 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
